Discovery and Development of New Antivirals for Smallpox

Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats

Volumn , Issue , 2005, Pages 330-351

  Kern, Earl R ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Acyclic nucleoside phosphonates; Cidofovir; Cowpox virus; Ectromelia virus; Monkeypox virus; Smallpox; Variola virus

Indexed keywords

EID: 84891010611     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0471716715.ch14     Document Type: Chapter

References (54)

1. Breman, J. G.; Henderson, D. A. Poxvirus delemmas-monkeypox, smallpox, and biological terrorism. N. Engl. J. Med. 1998, 339, 556-559.
2. Breman, J. G.; Henderson, D. A. Diagnosis and management of smallpox. N. Engl. J. Med. 2002, 346, 1300-1308.
3. Henderson, D. A. Bioterrorism as a public health threat. Emerging Infect. Dis. 1998, 4, 488-492.
4. Heymann, D. L.; Szczeniowski, M.; Esteves, K. Re-emergence of monkeypox in Africa: a review of the past six years. Br Med. Bull. 1998, 54, 693-702.
5. O'Toole, T. Smallpox: an attack scenario. Emerging Infect. Dis. 1999, 5, 540-546.
6. Hutin, Y. J.; Williams, R. J.; Malfait, P.; Pebody, R.; Loparev, V. N.; Ropp, S. L.; Rodriguez, M.; Knight, J. C.; Tshioko, F. K.; Khan, A. S.; Szczeniowski, M. V.; Esposito, J. J. Outbreak of human monkeypox, Democratic Republic of Congo, 1996-1997. Emerging Infect. Dis. 2001, 7, 434-438.
7. Bauer, D. J. The antiviral and synergic actions of isatin thiosemicarbazone and certain phenoxypyrimidines in vaccinia infection in mice. Br J. Exp. Pathol. 1955, 36, 105-114.
8. Bauer, D. J.; Sheffield, F. W. Antiviral chemotherapeutic activity of isatin β-thiosemi-carbazone in mice infected with rabbit-pox virus. Nature 1959, 184(Suppl 19), 1496-1497.
9. Boyle, J. J.; Haff, R. F.; Stewart, R. C. Evaluation of antiviral compounds by suppression of tail lesions in vaccinia-infected mice. Antimicrob. Agents Chemother 1966, 6, 536-539.
10. Bauer, D. J.; St. Vincent, L.; Kempe, C. H.; Downie, A. W. Prophylactic treatment of smallpox contacts with N-methylisatin β-thiosemicarbazone. Lancet 1963, 11, 494-496.
11. Bauer, D. J.; St Vincent, L.; Kempe, C. H.; Young, P. A.; Downie, A. W. Prophylaxis of smallpox with methisazone. Am. J. Epidemiol. 1969, 90, 130-145.
12. De Clercq, E.; De Somer, P. Effect of interferon, polyacrylic acid, and polymethacrylic acid on tail lesions on mice infected with vaccinia virus. Appl. Microbiol. 1968, 16, 1314-1319.
13. De Clercq, E.; Luczak, M.; Shugar, D.; Torrence, P. F.; Waters, J. A.; Witop, B. Effect of cytosine arabinoside, iododeoxyuridine, ethyldeoxyuridine, thiocyanatodeoxyuridine, and ribavirin on tail lesion formation in mice infected with vaccinia virus. Proc. Soc. Exp. Biol. Med. 1976, 151, 487-490.
14. De Clercq, E.; Holy, A.; Rosenberg, I.; Sakuma, T.; Balzarini, J.; Maudgal, P. C.. A novel selective broad-spectrum anti-DNA virus agent. Nature 1986, 323, 464-467.
15. De Clercq, E.; Sakuma, T.; Baba, M.; Pauwels, R.; Balzarini, J.; Rosenberg, I.; Holy, A. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res. 1987, 8, 261-272.
16. De Clercq, E.; Holy, A.; Rosenberg, I. Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo. Antimicrob. Agents Chemother. 1989, 33, 185-191.
17. Naesens, L.; Snoeck, R.; Andrei, G.; Balzarini, J.; Neyts, J.; De Clercq, E. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antiviral Chem. Chemother. 1997, 8, 1-23.
18. De Clercq, E. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin. Microbiol. Rev. 2001, 14, 382-397.
19. Neyts, J.; De Clercq, E. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cy-tosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. J. Med. Virol. 1993, 41, 242-246.
20. Baker, R. O.; Bray, M.; Huggins, J. W. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res. 2003, 57, 13-23.
21. Kern, E. R.; Hartline, C.; Harden, E.; Keith, K.; Rodriguez, N.; Beadle, J. R.; Hostetler, K. Y. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob. Agents Chemother. 2002, 46, 991-995.
22. Bray, M.; Martinez, M.; Smee, D. F.; Kefauver, D.; Thompson, E.; Huggins, J. W. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J. Infect. Dis. 2000, 181, 10-19.
23. Bray, M.; Martinez, M.; Kefauver, D.; West, M.; Roy, C. Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir. Antiviral Res. 2002, 54, 129-142.
24. Smee, D. F.; Bailey, K. W.; Wong, M. H.; Sidwell, R. W. Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir. Antiviral Res. 2000, 47, 171-177.
25. Smee, D. F.; Bailey, K. W.; Sidwell, R. W. Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir. Antiviral Chem. Chemother 2001, 12, 71-76.
26. Quenelle, D. C.; Collins, D. J.; Kern, E. R. Efficacy of multiple-or single-dose cidofovir against vaccinia and cowpox virus infections in mice. Antimicrob. Agents Chemother. 2003, 47, 3275-3280.
27. Huggins, J. W.; Martinez, M. J.; Hartmann, C. J.; Hensley, L. E.; Jackson, D. L.; Refoeven, D. F.; Kuksh, D. A.; Lawson, T.; Miller, D. M.; Mucker, E. A.; Shamblin, J. D.; Tate, M. K.; Whitehour, L. A.; Swiers, S. H.; Jahrling, P. B.. Successful cidofovir treatment of smallpox-like diseases in variola and monkeypox primate models. Antiviral Res. 2004, 62, A57.
28. Cundy, K. C.; Bidgood, A. M.; Lynch, G.; Shaw, J. P.; Griffin, L.; Lee, W. A. Pharmacokinetics, bioavailability, metabolism, and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats. Drug Metab. Dispos. 1996, 24, 745-752.
29. Cundy, K. C.; Li, Z. H.; Hitchcock, M. J.; Lee, W. A. Pharmacokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug. Drug Metab. Dispos. 1996, 24, 738-744.
30. Kern, E. R. In vitro activity of potential anti-poxvirus agents. Antiviral Res. 2003, 57, 35-40.
31. Safrin, S.; Cherrington, J.; Jaffe, H. S. Clinical uses of cidofovir. Rev. Med. Virol. 1997, 7, 145-156.
32. De Clercq, E. Cidofovir in the therapy and short-term prophylaxis of poxvirus infections. Trends Pharmacol. Sci. 2002, 23, 456-458.
33. Smee, D. F.; Sidwell, R. W. Anti-cowpox virus activities of certain adenosine analogs, arabinofuranosyl nucleosides, and 2'-fluoro-arabinofuranosyl nucleosides. Nucleosides Nucleotides Nucleic Acids 2004, 23, 375-383.
34. Barditch-Crovo, P.; Toole, J.; Hendrix, C. W.; Cundy, K. C.; Ebeling, D.; Jaffe, H. S.; Lietman, P. S. Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl) phosphonylmethoxyethy-l]adenine) in HIV-infected patients. J. Infect. Dis. 1997, 176, 406-413.
35. Neyts, J.; De Clercq, E. Efficacy of 2-amino-7-(1,3-dihydroxy-2-propoxymethyl)purine for treatment of vaccinia virus (orthopoxvirus) infections in mice. Antimicrob. Agents Chemother. 2001, 45, 84-87.
36. Smee, D. F.; Bailey, K. W.; Sidwell, R. W. Treatment of lethal cowpox virus respiratory infections in mice with 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine and its orally active diacetate ester prodrug. Antiviral Res. 2002, 54, 113-120.
37. De Clercq, E. In search of a selective antiviral chemotherapy. Clin. Microbiol. Rev. 1997, 10, 674-693.
38. De Clercq, E. Cidofovir in the treatment of poxvirus infections. Antiviral Res. 2002b, 55, 1-13.
39. Keith, K. A.; Hitchcock, M. J.; Lee, W. A.; Holy, A.; Kern, E. R. Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication. Antimicrob. Agents Chemother. 2003, 47, 2193-2198.
40. Smee, D. F.; Bailey, K. W.; Sidwell, R. W. Treatment of cowpox virus respiratory infections in mice with ribavirin as a single agent or followed sequentially by cidofovir. Antiviral Chem. Chemother. 2000, 11, 303-309.
41. Smee, D. F.; Bailey, K. W.; Wong, M. H.; Sidwell, R. W. Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice. Antiviral Res. 2001, 52, 55-62.
42. Roy, C. J.; Baker R.; Washburn, K.; Bary, M. Aerosolized cidofovir is retained in the respiratory tract and protects mice against intranasal cowpox virus challenge. Antimicrob. Agents Chemother. 2003, 47, 2933-2937.
43. Snoeck, R.; Holy, A.; Dewolf-Peeters, C.; Van Den Oord, J.; De Clercq, E.; Andrei, G. Antivaccinia activities of acyclic nucleoside phosphonate derivatives in epithelial cells and organotypic cultures. Antimicrob. Agents Chemother. 2002, 46, 3356-3361.
44. Hostetler, K. Y.; Beadle, J. R.; Kini, G. D.; Gardner, M. F.; Wright, K. N.; Wu, T. H.; Korba, B. A. Enhanced oral absorption and antiviral activity of 1-O-octadecyl-sn-glycero-3-phospho-acyclovir and related compounds in hepatitis B virus infection, in vitro. Biochem. Pharmacol. 1997, 53, 1815-1822.
45. Hostetler, K. Y.; Rybak, R. J.; Beadle, J. R.; Gardner, M. F.; Aldern, K. A.; Wright, K. N; Kern, E. R. In vitro and in vivo activity of 1-O-hexadecylpropanediol-3-phospho-ganciclovir and 1-O-hexadecylpropanediol-3-phospho-penciclovir in cytomegalovirus and herpes simplex virus infections. Antiviral Chem. Chemother. 2001, 12, 61-70.
46. Hostetler, K. Y.; Beadle, J. R.; Hornbuckle, W. E.; Bellezza, C. A.; Tochkov, I. A.; Cote, P. J.; Gerin, J. L.; Korba, B. E.; Tennant, B. C. Antiviral activities of oral 1-O-hexadecyl-propanediol-3-phosphoacyclovir and acyclovir in woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob. Agents Chemother. 2000, 44, 1964-1969.
47. Huggins, J. W.; Baker, R. O.; Beadle, J. R.; Hostetler, K. Y. Orally active ether lipid prodrugs of cidofovir for the treatment of smallpox. Antiviral Res. 2002, 53, A66.
48. Buller, R. M.; Owens, G.; Schriewer, J.; Melman, L.; Beadle, J. R.; Hostetler, K. Y. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 2004, 318, 474-481.
49. Beadle, J. R.; Hartline, C. B.; Aldern, K. A.; Rodriguez, N.; Harden, E.; Kern, E. R.; Hostetler, K. Y. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob. Agents Chemother. 2002, 46, 2381-2386.
50. Hartline, C. B.; Gustin, K. M.; Wan, W. B.; Ciesla, S. L.; Beadle, J. R.; Hostetler, K. Y.; Kern, E. R. Ether lipid ester prodrugs of acyclic nucleoside phosphonates: Activity against adenovirus replication in vitro. J. Infect. Dis. 2005, 191, 396-399.
51. Keith, K. A.; Wan, W. B.; Ciesla, S. L.; Beadle, J. R.; Hostetler, K. Y.; Kern, E. R. Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro. Antimicrob. Agents Chemother. 2004, 48, 1869-1871.
52. Aldern, K. A.; Ciesla, S. L.; Winegarden, K. L.; Hostetler, K. Y. Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol. Pharmacol. 2003, 63, 678-681.
53. Ciesla, S. L.; Trahan, J.; Wan, W. B.; Beadle, J. R.; Aldern, K. A.; Painter, G. R.; Hostetler, K. Y. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res. 2003, 59, 163-171.
54. Quenelle, D. C.; Collins, D. J.; Wan, W. B.; Beadle, J. R.; Hostetler, K. Y.; Kern, E. R. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob. Agents Chemother. 2004, 48, 404-412.